September 2025 Quarterly Production Update

FY2026 Group Guidance of 160,000 AuEq oz to 175,000 AuEq oz production at an AISC of A$2,600 - $2,900 per AuEq oz remains ...
Pharmabiz

Regeneron gests US FDA approval for Libtayo as an adjuvant treatment of CSCC with a high risk of recurrence after surgery and radiation

Regeneron gests US FDA approval for Libtayo as an adjuvant treatment of CSCC with a high risk of recurrence after surgery and radiation: Tarrytown, New York Friday, October 10, 20 ...

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to ...
PharmiWeb

FDA Approves Libtayo as First Immunotherapy for Adjuvant Treatment of CSCC

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.

Recursion Pharmaceuticals: Recent Gains Are Mysterious Given A Lack Of Overall Progress

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage ...
Targeted Oncology

Selecting Second-Line Treatment in HR+, HER2-Low Breast Cancer

Claudine Isaacs, MD: For this patient who's progressed after more than 12 months with an ESR1 mutation and HER2-low disease ...
Junior Mining Network

Alkane Resources: September 2025 Quarterly Production Update

FY2026 Group Guidance of 160,000 AuEq oz to 175,000 AuEq oz production at an AISC of A$2,600 - $2,900 per AuEq oz remains unchanged.3 ...